Abbott on Monday announced positive results from a mid-stage study demonstrating that its experimental endothelin A receptor antagonist, atrasentan, may reduce albuminuria among patients with type 2 diabetic nephropathy when used in conjunction with renin-angiotensin system inhibitors.
The study randomised 89 patients with diabetic nephropathy on stable doses of renin-angiotensin system inhibitors for at least 2 months to receive one of three doses of atrasentan or placebo for eight weeks. Data show that the medium dose of atrasentan reduced urine albumin-to-creatinine (UACR) ratio by 42 percent, versus a reduction of 34 percent and 21 percent among the highest and lowest dose, respectively. By comparison, UACR was reduced by 11 percent in patients given placebo. Further, half of patients treated with the medium dose of atrasentan achieved a significant, greater than 40 percent reduction in UACR from baseline, compared to 17 percent of patients in the placebo arm.
Commenting on the data, which was announced at the American Society of Nephrology meeting, lead investigator Donald Kohan said "these study results are encouraging and suggest that atrasentan may have an additional therapeutic role for albuminuria reduction on top of the current standard of care for patients with type 2 diabetes."
Reference Articles
Abbott announces positive results from Phase 2 study of low dose atrasentan for treatment of diabetic kidney disease - (Abbott)
Abbott drug meets goals in kidney disease study - (MSN Money)
Abbott reports positive results from Phase 2 study of low dose atrasentan - (Stock Markets Review)
**Published in "First Word"
No comments:
Post a Comment